Adimmune Corporation (TPE: 4142)
Taiwan
· Delayed Price · Currency is TWD 26.95
-0.45 (-1.64%)
Sep 11, 2024, 1:30 PM CST
Adimmune Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,657 | 1,785 | 2,252 | 1,794 | 1,869 | 1,300 | Upgrade
|
| Revenue Growth (YoY) | -13.91% | -20.72% | 25.52% | -4.03% | 43.81% | 58.04% | Upgrade
|
| Cost of Revenue | 1,196 | 1,374 | 1,361 | 1,177 | 1,246 | 1,132 | Upgrade
|
| Gross Profit | 460.89 | 410.94 | 891.08 | 616.86 | 623.06 | 167.59 | Upgrade
|
| Selling, General & Admin | 469.62 | 442.87 | 446.11 | 349.67 | 311.19 | 230.93 | Upgrade
|
| Research & Development | 289.31 | 296.93 | 346.42 | 321.28 | 337.68 | 235.64 | Upgrade
|
| Operating Expenses | 1,133 | 1,134 | 797.52 | 670.95 | 648.88 | 466.57 | Upgrade
|
| Operating Income | -672.08 | -722.75 | 93.57 | -54.09 | -25.81 | -298.98 | Upgrade
|
| Interest Expense | -40.35 | -33.43 | -22.59 | -14.69 | -22.16 | -41.06 | Upgrade
|
| Interest & Investment Income | 27.36 | 26.2 | 14.89 | 12.58 | 11.99 | 12.41 | Upgrade
|
| Currency Exchange Gain (Loss) | -14.17 | -31.38 | 52.62 | 4.28 | -15.27 | -7.57 | Upgrade
|
| Other Non Operating Income (Expenses) | -42.02 | -8.85 | 17.72 | 8.32 | 28.01 | 20.95 | Upgrade
|
| EBT Excluding Unusual Items | -741.26 | -770.21 | 156.21 | -43.6 | -23.26 | -314.24 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 1.44 | -0.72 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.02 | -0.04 | 0.01 | 0.01 | 0.16 | 0.09 | Upgrade
|
| Legal Settlements | - | - | - | -4.39 | 1,159 | - | Upgrade
|
| Other Unusual Items | 0 | 0.26 | - | 62.27 | 59.63 | 0.27 | Upgrade
|
| Pretax Income | -741.28 | -769.98 | 156.22 | 14.29 | 1,197 | -314.59 | Upgrade
|
| Income Tax Expense | - | - | 10 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -741.28 | -769.98 | 146.22 | 14.29 | 1,197 | -314.59 | Upgrade
|
| Minority Interest in Earnings | 133.36 | 130.09 | 144.76 | 28.78 | 43.98 | 33.91 | Upgrade
|
| Net Income | -607.92 | -639.89 | 290.98 | 43.07 | 1,241 | -280.68 | Upgrade
|
| Net Income to Common | -607.92 | -639.89 | 290.98 | 43.07 | 1,241 | -280.68 | Upgrade
|
| Net Income Growth | - | - | 575.65% | -96.53% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 422 | 422 | 427 | 430 | 409 | 310 | Upgrade
|
| Shares Outstanding (Diluted) | 422 | 422 | 428 | 430 | 410 | 310 | Upgrade
|
| Shares Change (YoY) | -0.44% | -1.44% | -0.45% | 4.77% | 32.11% | 31.74% | Upgrade
|
| EPS (Basic) | -1.44 | -1.52 | 0.68 | 0.10 | 3.03 | -0.90 | Upgrade
|
| EPS (Diluted) | -1.45 | -1.52 | 0.68 | 0.10 | 3.03 | -0.90 | Upgrade
|
| EPS Growth | - | - | 580.00% | -96.70% | - | - | Upgrade
|
| Free Cash Flow | -261.56 | -1,270 | -711.4 | -1,325 | 1,785 | -503.39 | Upgrade
|
| Free Cash Flow Per Share | -0.62 | -3.01 | -1.66 | -3.08 | 4.35 | -1.62 | Upgrade
|
| Dividend Per Share | - | - | - | - | 0.500 | - | Upgrade
|
| Gross Margin | 27.82% | 23.02% | 39.58% | 34.39% | 33.33% | 12.89% | Upgrade
|
| Operating Margin | -40.57% | -40.49% | 4.16% | -3.02% | -1.38% | -23.00% | Upgrade
|
| Profit Margin | -36.70% | -35.85% | 12.92% | 2.40% | 66.41% | -21.60% | Upgrade
|
| Free Cash Flow Margin | -15.79% | -71.15% | -31.60% | -73.84% | 95.49% | -38.73% | Upgrade
|
| EBITDA | -481.34 | -528.03 | 326.68 | 150.76 | 181.27 | -81.57 | Upgrade
|
| EBITDA Margin | -29.06% | -29.58% | 14.51% | 8.40% | 9.70% | -6.28% | Upgrade
|
| D&A For EBITDA | 190.74 | 194.72 | 233.12 | 204.85 | 207.08 | 217.41 | Upgrade
|
| EBIT | -672.08 | -722.75 | 93.57 | -54.09 | -25.81 | -298.98 | Upgrade
|
| EBIT Margin | -40.57% | -40.49% | 4.16% | -3.02% | -1.38% | -23.00% | Upgrade
|
| Effective Tax Rate | - | - | 6.40% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.